• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Radiology Classics

INPULSIS: Nintedanib for Idiopathic Pulmonary Fibrosis [Classics Series]

byDeepti Shroff Karhade
June 16, 2022
in Radiology Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. In this report of two randomized, placebo-controlled trials, nintedanib reduced force vital capacity decline in patients with idiopathic pulmonary fibrosis versus control over 52 weeks.

2. Nintedanib was relatively safe, with its most frequent adverse event being diarrhea.

Original Date of Publication: May 2014

Study Rundown: The INPULSIS 1 and 2 trials sought to evaluate the efficacy of nintedanib, an intracellular tyrosine kinase inhibitor, in the treatment of idiopathic pulmonary fibrosis. Overall, the rate of decline of forced vital capacity (FVC), a surrogate for disease progression, was significantly reduced in those receiving nintedanib (P < 0.001 in both trials). The INPULSIS-2 trial additionally found a significant increase in the time to first disease exacerbation in the treatment group (P = 0.005), however INPULSIS-1 did not. Diarrhea was the most frequently reported adverse event in both groups, usually mild to moderate in intensity, leading to discontinuation for less than 5% of participants in both trials. The rate of serious adverse events did not differ significantly versus placebo for both trials. Although this is a well-designed trial offering convincing support for the use of nintedanib in idiopathic pulmonary fibrosis, it has several limitations. It failed to show a clear effect of nintedanib on improved time to first acute exacerbation of disease, an important endpoint given its high association with morbidity and mortality.

Click to read the study in NEJM

In-Depth [randomized control trial]: The INPULSIS-1 and 2 trials randomized 1066 and 515 patients, respectively, between May 2011 and September 2012 at 205 sites internationally. All patients were 40 years or older with a diagnosis of idiopathic pulmonary fibrosis in the past 5 years. Patients were randomized to receive either 150mg of nintedanib twice daily or placebo for a total of 52 weeks, with spirometric testing for FVC performed periodically during this period. Overall, the adjusted annual decline in FVC was significantly reduced in the treatment group for both trials (P < 0.001 for both). Time to first acute exacerbation was similar between treatment groups for INPULSIS-1 (P = 0.67), however was significantly lower in the nintedanib group for INPULSIS-2 (P = 0.005). There was no significant difference in deaths from any cause in either trial. Over 90% of patients in both trials reported mild to moderate diarrhea when using nintedanib. Serious adverse events did not differ significantly between groups.

RELATED REPORTS

Exposure to particulate matter 2.5 ÎĽm or less associated with adverse outcomes among patients with fibrotic interstitial lung disease

#VisualAbstract: Phosphodiesterase 4 inhibitor BI 1015550 preserves lung function in pulmonary fibrosis patients

Nintedanib may be effective in slowing the progression of interstitial lung disease

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 2014 May 29;370(22):2071–82.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: force vital capacityidiopathic pulmonary fibrosisnintedanib
Previous Post

Plant-based CoVLP+AS03 vaccine protects against COVID-19 infection

Next Post

Screening with digital breast tomosynthesis vs mammography associated with significantly lower risk of advanced breast cancer among women with extremely dense breasts at high risk of breast cancer

RelatedReports

Lessons from real-world implementation of lung cancer screening
Chronic Disease

Exposure to particulate matter 2.5 ÎĽm or less associated with adverse outcomes among patients with fibrotic interstitial lung disease

October 27, 2022
#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients
StudyGraphics

#VisualAbstract: Phosphodiesterase 4 inhibitor BI 1015550 preserves lung function in pulmonary fibrosis patients

June 29, 2022
Recurrent hemoptysis is effectively treated by bronchial artery embolization
Chronic Disease

Nintedanib may be effective in slowing the progression of interstitial lung disease

July 18, 2020
The SENSCIS trial: nintedanib slows declines in FVC in patients with interstitial lung disease caused by systemic sclerosis
Chronic Disease

The SENSCIS trial: nintedanib slows declines in FVC in patients with interstitial lung disease caused by systemic sclerosis

May 26, 2019
Next Post
2 Minute Medicine Rewind March 4, 2019

Screening with digital breast tomosynthesis vs mammography associated with significantly lower risk of advanced breast cancer among women with extremely dense breasts at high risk of breast cancer

Wellness Check: Spirituality

Interstitial lung abnormalities linked to greater risk of all-cause mortality

Phosphodiesterase 4 inhibitor BI 1015550 preserves lung function in pulmonary fibrosis patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options